StockData
Theriva Biologics, Inc. logo

Theriva Biologics, Inc. (TOVX) stock

TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.12−0.01 (-6.25%)

Close on Nov 20, 2026Market cap $5.51MP/E –Yield –

Theriva Biologics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Theriva Biologics's net income for the twelve months ending Dec 31, 2023 was -$18.35M. For fiscal 2023 it was -$18.35M. The highest annual figure on record is -$1.71M in fiscal 2010.

Annual net income

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$18.35M–
FY2022Dec 31, 2022-$19.69M–
FY2021Dec 31, 2021-$14.27M–
FY2020Dec 31, 2020-$10.04M–
FY2019Dec 31, 2019-$15.30M–
FY2018Dec 31, 2018-$13.37M–
FY2017Dec 31, 2017-$15.17M–
FY2016Dec 31, 2016-$27.26M–
FY2015Dec 31, 2015-$43.74M–
FY2014Dec 31, 2014-$19.78M–
FY2013Dec 31, 2013-$12.32M–
FY2012Dec 31, 2012-$17.07M–
FY2011Dec 31, 2011-$8.15M–
FY2010Dec 31, 2010-$1.71M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$5.49M–
Q3 FY2023Sep 30, 2023-$3.30M–
Q4 FY2022Dec 31, 2022-$6.45M–
Q3 FY2022Sep 30, 2022-$4.49M–
Q2 FY2022Jun 30, 2022-$4.48M–
Q1 FY2022Mar 31, 2022-$4.27M–
Q4 FY2021Dec 31, 2021-$5.26M–
Q3 FY2021Sep 30, 2021-$3.27M–
Q2 FY2021Jun 30, 2021-$3.20M–
Q1 FY2021Mar 31, 2021-$2.54M–
Q4 FY2020Dec 31, 2020-$2.11M–
Q3 FY2020Sep 30, 2020-$2.10M–
Q2 FY2020Jun 30, 2020-$2.87M–
Q1 FY2020Mar 31, 2020-$2.96M–
Q4 FY2019Dec 31, 2019-$3.14M–
Q3 FY2019Sep 30, 2019-$5.12M–
Q2 FY2019Jun 30, 2019-$3.53M–
Q1 FY2019Mar 31, 2019-$3.51M–
Q4 FY2018Dec 31, 2018-$3.19M-213.5%
Q3 FY2018Sep 30, 2018-$3.68M–
Q2 FY2018Jun 30, 2018-$4.20M–
Q1 FY2018Mar 31, 2018-$2.32M–
Q4 FY2017Dec 31, 2017$2.81M–
Q3 FY2017Sep 30, 2017-$10.93M–
Q2 FY2017Jun 30, 2017-$4.32M–
Q1 FY2017Mar 31, 2017-$3.06M–
Q4 FY2016Dec 31, 2016-$2.47M–
Q3 FY2016Sep 30, 2016-$8.49M–

More Theriva Biologics figures

See a number that looks wrong?